Drug Index


Mechanism :

Evolocumab is a human monoclonal antibody (IgG2 isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on hepatocyte surfaces to promote LDLR degradation within the liver.

Indication :

  • Homozygous familial hypercholesterolemia
  • Primary hyperlipidemia (including heterozygous familial hyperlipidemia)

Contraindications :

Serious hypersensitivity to evolocumab or any component of the formulation.

Dosing :

Adolescents 13 to 17 years:
Homozygous familial hypercholesterolemia:
SC 420 mg once monthly.
Primary Hyperlipidemia:
SC 140 mg every 2 weeks or 420 mg once monthly.
Note: Use in combination with diet and other lipid-lowering therapies.

Adverse Effect :

Nasopharyngitis, hypertension, dizziness, fatigue, skin rash, gastroenteritis, UTI, influenza, injection site reaction, myalgia.

Interaction :

Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.

Hepatic Dose :

Mild hepatic impairment: No dosage adjustment needed.
Moderate and severe hepatic impairment: Use not recommended
02/20/2024 23:17:36 Evolocumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0